June 4, 2025 10:00 AM EDT
People
Pharma
In Focus

Strug­gling biotechs suc­cumb to icy mar­ket, as mon­ey dries up and clin­i­cal bets don’t pay off

Kyle LaHucik

Biotech Correspondent

In the span of 15 days, the fate of iTeos Ther­a­peu­tics soured quick­ly.

Once a bea­con of the an­ti-TIG­IT class, the com­pa­ny this spring faced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Oma­da Health is go­ing pub­lic on Fri­day at a $1.1B val­u­a­tion

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

A decade af­ter its ill-fat­ed $40.5B megadeal, Te­va piv­ots from gener­ics to in­no­va­tion

FDA's Makary looks at ways to speed drug ap­provals, talks about cut­ting user fees

Trump's health ap­pointees pledge sup­port for cell and gene ther­a­pies at FDA round­table

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times